secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0000950170-24-120282
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio files first regulatory submission for KRRO-110 in AATD, expects first dosing Q1 2025
--------------------------------------------------------------------------------

- Regulatory filing submitted to Australian Bellberry HREC for Phase 1/2 study of KRRO-110 in Alpha-1 Antitrypsin Deficiency.
- First participant dosing anticipated in Q1 2025; interim readout expected H2 2025; study completion in 2026.
- Formed Clinical Advisory Board of six lung and liver experts to guide development strategy.
- KRRO-110 is first RNA editing oligonucleotide from Korro's OPERA platform, targeting SERPINA1 RNA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024120282/0000950170-24-120282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024120282/krro-20241104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-120282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer